Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 30; no. 6; pp. 1405 - 1409
Main Authors:	Lasater, E A, Massi, E S, Stecula, A, Politi, J, Tan, S K, Smith, C C, Gunthorpe, M, Holmes, J P, Chehab, F, Sali, A, Shah, N P
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-06-2016 Nature Publishing Group
Subjects:	13 13/95 631/208/212/1728 631/208/737 631/67/1990/283/1896 692/308/575 692/699/67/1059/99 96/106 Axitinib Cancer Research Chronic myeloid leukemia Critical Care Medicine Drug resistance Drug therapy Gene mutations Genetic aspects Growth factors Health aspects Hematology Intensive Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Medicine Medicine & Public Health Mutation Oncology Patient outcomes Patients
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2015.303